{"name":"ImmunOs Therapeutics AG","slug":"immunos-therapeutics-ag","ticker":"","exchange":"","domain":"immunos.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOeEhLT1NVMXhmU2ZUVHZwRV9xV1hCZXZMMHZob0prRkI1aDdxYTJ3ODQ3emVfank1bUg3MlNLR2FFSFprTkpfNThPdDRQVHAxV0xuWENmbGFtTGgwZnlHUXA0dW5mYXBsWlh6Ylo3LVlGZmNDTjV6VHFFV2w2R2drUGd6elcxWEVEMU5qMGlXTEwtNWlqQXFMMWdMckxLRTRs?oc=5","date":"2025-12-09","type":"pipeline","source":"Fierce Biotech","summary":"Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech - Fierce Biotech","headline":"Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFBNa0pTM28zMmtaczdsdEw0MS1GRzFBai13Mjd6SS1mZEtVcG8xMVU4OXV6cnh6MUJhdnNjNlZQdGJ4cUpfSUMwNWdUVUx1bVZKandRbkt1S00zYjlkVFNXal9aMGFQS2dHUXFJcG56MzhzU1hpcXc?oc=5","date":"2025-11-12","type":"pipeline","source":"Labiotech.eu","summary":"19 swiss biotech startups you’ll want to keep an eye on - Labiotech.eu","headline":"19 swiss biotech startups you’ll want to keep an eye on","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxONUcyZkZtLVFSSWFpdGhncGlEYXF3OVZNV0lrMzB0M1dKNlhQUHFuLXZfT1V4NGdMSnV0UC1VektMVFA0SV8wQmd1LWxFTDZlZ2FlWlVHY3hYdjlEbEtIM3ctX2NqbHdkaTBpYnUwODdVTjNPR0xjeTFjTnZZejhVMHVnQ3JRcEoyS3lOSUtlcFBhRGc?oc=5","date":"2025-11-06","type":"pipeline","source":"Insightace Analytic","summary":"Immuno-Oncology Cell Therapy Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Immuno-Oncology Cell Therapy Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNTkdyTnI4REROaGRoYkdFQ3BXZDlqcDNUeE9VT1lHMVAtaXpua3Fnb2o2Ull3MWJUVkFhbkV4aU5jQkFxcDFGMzBBU2ZwcTRLWlQ2NDU4MWRxc1RxUkNrX3h1MnlNOGM2U0stWUxzTTZVbTBVdFE5bjdZdmtnWWg1TGdVcUd1WUJ4TEJfd0w4d2t0ajZEcXgzT2NPenZKU3JVakR2dXJKV1gwcmVwZVJPMnJmbzZxZVRDZTd3VmxrYnh1bmUteDRFRWt0b1JBQzJEYlcxM25SREU4elBGd09acnpuQkdianhnQVQtQVpMM0lOT3NuWnY2WFB2VS1reVRPMkJPMkxSMXZ0bHloMU1ydHJEdDJ1TDNzd3JEUzRxNUlCWnNKWm4tZ1YtdXBmdw?oc=5","date":"2025-10-23","type":"regulatory","source":"PR Newswire","summary":"Apotex Receives Health Canada Approval for LOQTORZI® -- The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer - PR Newswire","headline":"Apotex Receives Health Canada Approval for LOQTORZI® -- The First and Only Immuno-Therapy for Recurrent Unresectable or ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE8tNm9uclRjeTJjcEpUbmhLTHR4SlY5TTREWlBmbTdLaU9FSkxZQ19yY1NNRW1SZVdoZkU4OVJtTnBldzFvU3ljYjEyMHRRV2FCR0dWQ09LNFNqQkswTnZmWlU3aDNjbFdvRGtlaU15b2NsaWViYjlMMzNmOA?oc=5","date":"2025-07-24","type":"trial","source":"globaldata.com","summary":"Immuno-oncology: Strategic Intelligence - globaldata.com","headline":"Immuno-oncology: Strategic Intelligence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOTHJOVWF0RDhlNEgwNVZFd2RhUU15MWQxbmpGZWh2VUU0NFVqSnpYZUc3R1BqWWVtTUxCeENLa3h6X25ZYTNOYkZZZ0FxcG9VdFdvd2gxYVdIcEVqN1BRZTRaWkQwX1E0azBNVlRBd19NUVRVazY3THBWZ1RwZGlIMnZUeEZzVjlXLU5YaXhNcDYyb3lTcWstV0JoWk5ydWdoR1A0aVJOTWdsUGRPRnpIWWRvWEFyOGRoRTY4Z0lJdkplTjRBVURsbWE1WFpUUUhQME8tZHNsMFl6TDgzeVI3WGtfWmhhRGl3eHc?oc=5","date":"2025-06-16","type":"deal","source":"Koreabizwire","summary":"Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology - Koreabizwire","headline":"Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Onc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQR3FOSnkzeTI2YUtMMEQwT0dScDBxM3BWc2NuZG1kRTJnRkRtRC1BTFAtV0RiZWJ0MFBub0x1aWpFUG9ETXlKZUttaGZRMnEzZkwtMjMweDBKcmZ3THRXUHlWUndMZmQ2eFJJMlQxRGRQOW1sN0hMMl9jeVNhbkZkLV9ZN25hQnRJU0JyNVJWWThMamRRV0ZoZVBVMW5BOUtwODg1eDJpM2wxX0VqN003Ng?oc=5","date":"2024-07-29","type":"deal","source":"BioSpace","summary":"Boehringer Buys Nerio Therapeutics for $1.3B to Boost Immuno-Oncology Pipeline - BioSpace","headline":"Boehringer Buys Nerio Therapeutics for $1.3B to Boost Immuno-Oncology Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTE1FNHFUU1F6OVJOUC1sZGNySzQ4Ri1SdWFKcFRDeDNNVDgxQXJodFNyS003U29lQ3l5cklzS3FXMlo2M2F0M04tT1hNN0M?oc=5","date":"2024-07-10","type":"deal","source":"Oncodaily","summary":"APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million - Oncodaily","headline":"APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNNU9EVkZxS09XUkhlbzVxWnU0MU9jU29DRU1BclJoeWZDUTE4NHdzT0NyR0g5X18zc1lCU0JJZWNSS05mdUhPZmJoRi1YTkVIZVg2enZHNEZQS3V6cFlETHZ5eDNYOXVlVTlrdG5QbWhiSEVBVVNDcS1aUGxfZWMyb3d1NXVqbDJYYUZJN0JwMnpMOUtjVklLaHBYaW13VFVYUEtRal8wRGw3cDA0Tk5vb1JHQk9hWDVidDA5U3RrRTE1WUo1X2puNmlPS0V0czBYWkFuM3VDYUtHYWhVdmptNVZCN2g0QWk4SnFyU3FrT2xUeGJ3QUNWcUNYbUE3V0l6S0lHd3pyM1JzMjhKaFE?oc=5","date":"2023-11-22","type":"pipeline","source":"Business Wire","summary":"Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma - Business Wire","headline":"Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Ph","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNRUhtQXFKQU9oa19lVUMxRUxrRzUxQ2R0c0tRZy14OFpqSjgtMkxrRDJ0YmgwNk0zbzIwY3VIY2doMjFZeDQtekM4bk1NOFFRTVEwTjZtX2lRRHc3UzFQX3haRjJmZG9CRDJDY0V1VExDMEI1bGEycnh6SENGYWV5dkVYcDlJdWVVdThmdjZib2ZsSWFwbkNFZWliUVhQc3hjVXJMWVk1ZWg5RVFTRHhUcmdqQmMwd1U3MXVtaE53b0FLaXBTSUJ3?oc=5","date":"2023-05-12","type":"pipeline","source":"Pharmaceutical Technology","summary":"Who are the leading innovators in CAR-T cell-based compositions for the pharmaceutical industry? - Pharmaceutical Technology","headline":"Who are the leading innovators in CAR-T cell-based compositions for the pharmaceutical industry?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE5Bemk1aVdOZWdfSGNwUW8zZ1ZqaERzM1hwQ205SzkwVlZFZzFwQWQ4Y01YQTRWNlVlc3NIR3hlN2N6SkVMUWhlYjl4NlVCWmMwQmJTLXQ2VVpDUU9MSHE4TDJR?oc=5","date":"2022-06-21","type":"pipeline","source":"Labiotech.eu","summary":"ImmunOs Therapeutics raises $74M - Labiotech.eu","headline":"ImmunOs Therapeutics raises $74M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPZlR1U014ZHpLOURsT3ZVOVBJZ21PeTN2VlJlWDVjejdSUTFVUzdFU3REelVVeGtLWWE5UjBJbUpucWVOZjVxWGIyLTdSQ0pOMnFPTWF3ZlpibURNYnZwWlB3Wm5KVnJlemhpVV9veU9kbkVHZXNrdlV4c3FVUDVTcW9mdWVkX0hfWFRPT3FTYUFOV0VqazdlZQ?oc=5","date":"2020-05-07","type":"pipeline","source":"The Pharmaceutical Journal","summary":"Immuno-oncology agents for cancer therapy - The Pharmaceutical Journal","headline":"Immuno-oncology agents for cancer therapy","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}